Lymphotoxin beta‐activated LTBR/NIK/RELB axis drives proliferation in cholangiocarcinoma
Liver International · 2024
DOI: 10.1111/liv.16069 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2024. Verfasst von Kaiyu Xu und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg University Hospital, Heidelberg, Germany. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Lymphotoxin beta Receptor, Bile Duct Neoplasms, Transcription Factor RelB. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe.
Abstract (Originalsprache)
Background and Aims Cholangiocarcinoma (CCA) is an aggressive malignancy arising from the intrahepatic (iCCA) or extrahepatic (eCCA) bile ducts with poor prognosis and limited treatment options. Prior evidence highlighted a significant contribution of the non‐canonical NF‐κB signalling pathway in initiation and aggressiveness of different tumour types. Lymphotoxin‐β (LTβ) stimulates the NF‐κB‐inducing kinase (NIK), resulting in the activation of the transcription factor RelB. However, the functional contribution of the non‐canonical NF‐κB signalling pathway via the LTβ/NIK/RelB axis in CCA carcinogenesis and progression has not been established.
Methods
Human CCA‐derived cell lines and organoids were examined to determine the expression of NF‐κB pathway components upon activation or inhibition. Proliferation and cell death were analysed using real‐time impedance measurement and flow cytometry. Immunoblot, qRT‐PCR, RNA sequencing and in situ hybridization were employed to analyse gene and protein expression. Four in vivo models of iCCA were used to probe the activation and regulation of the non‐canonical NF‐κB pathway.
Results
Exposure to LTα1/β2 activates the LTβ/NIK/RelB axis and promotes proliferation in CCA. Inhibition of NIK with the small molecule inhibitor B022 efficiently suppresses RelB expression in patient‐derived CCA organoids and nuclear co‐translocation of RelB and p52 stimulated by LTα1/β2 in CCA cell lines. In murine CCA, RelB expression is significantly increased and LTβ is the predominant ligand of the non‐canonical NF‐κB signalling pathway.
Conclusions
Our study confirms that the non‐canonical NF‐κB axis LTβ/NIK/RelB drives cholangiocarcinogenesis and represents a candidate therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg University Hospital, Heidelberg, Germany.
- Liver Cancer Center Heidelberg, Heidelberg University Hospital, Heidelberg, Germany.
- Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.
- Department of Medicine A, Hematology, Oncology, Hemostaseology and Pneumology, University Hospital Münster, Münster, Germany.
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
- Computational Oncology, Molecular Diagnostics Program, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
ORCID-Profile: Kaiyu Xu, Thomas Albrecht, Bruno C Köhler
Förderung
- Deutsche Forschungsgemeinschaft
- Deutsche Krebshilfe
Zitieren
APA
Xu, K., Kessler, A., Nichetti, F., Hoffmeister-Wittmann, P., Scherr, A. L., Nader, L., Kelmendi, E., Schmitt, N., Schwab, M., García-Beccaria, M., Sobol, B., Nieto, O. A., Isele, H., Gärtner, U., Vaquero-Siguero, N., Volk, J., Korell, F., Mock, A., Heide, D., …, & Köhler, B. C. (2024). Lymphotoxin beta‐activated LTBR/NIK/RELB axis drives proliferation in cholangiocarcinoma. Liver International. https://doi.org/10.1111/liv.16069
Vancouver
Xu K, Kessler A, Nichetti F, Hoffmeister-Wittmann P, Scherr AL, Nader L, et al. Lymphotoxin beta‐activated LTBR/NIK/RELB axis drives proliferation in cholangiocarcinoma. Liver International. 2024. doi:10.1111/liv.16069
BibTeX
@article{Xu2024,
author = {Xu, Kaiyu and Kessler, Annika and Nichetti, Federico and Hoffmeister-Wittmann, Paula and Scherr, Anna-Lena and Nader, Luisa and Kelmendi, Eblina and Schmitt, Nathalie and Schwab, Maximilian and García-Beccaria, María and Sobol, Benjamin and Nieto, Osama Azzam and Isele, Hanna and Gärtner, Ulrike and Vaquero-Siguero, Nuria and Volk, Julia and Korell, Felix and Mock, Andreas and Heide, Danijela and Ramadori, Pierluigi and Lenoir, Bénédicte and Albrecht, Thomas and Hüllein, Jennifer and Jäger, Dirk and Fröhling, Stefan and Springfeld, Christoph and Jackstadt, Rene and Heikenwälder, Mathias and Dill, Michael T and Roessler, Stephanie and Goeppert, Benjamin and Köhler, Bruno C},
title = {Lymphotoxin beta‐activated LTBR/NIK/RELB axis drives proliferation in cholangiocarcinoma},
journal = {Liver International},
year = {2024},
doi = {10.1111/liv.16069}
}
EUVIMED